Takayasu arteritis
Drug research and approvals for takayasu arteritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 18 studies of takayasu arteritis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 18
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Global Initiative on Takayasu Arteritis (GITA)NCT07558382 · Not reported · Marmara University · starts Aug 5, 2025
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained RemissionNCT07491913 · Not applicable · Marmara University · starts Jun 15, 2025
- Investigating Management, Perspectives and Attitudes Towards Care in Takayasu ArteritisNCT07351422 · Not reported · University of Edinburgh · starts Oct 1, 2025
- Physical and Psychosocial Parameters in Takayasu Arteritis and Behçet's Disease: A Comparative Study With Healthy…NCT07276087 · Not reported · ÖZLEM NUR TOK YAMAN · starts Sep 11, 2025
- Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries InvolvementNCT07184814 · Not reported · China-Japan Friendship Hospital · starts Jan 1, 2016
- Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic DiseasesNCT07087912 · Phase 4 · University of Sao Paulo General Hospital · starts Mar 16, 2026
- EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular DiseasesNCT07077304 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Nov 19, 2025
- Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)NCT06887062 · Phase 2 · University of Edinburgh · starts Mar 21, 2025
- A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision…NCT06498089 · Phase 4 · Shanghai Zhongshan Hospital · starts Jun 28, 2024
Phase 3 6
- TocilizumabInterleukin-6 receptor alpha subunit inhibitor
- AzathioprineAmidophosphoribosyltransferase inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- TofacitinibJanus Kinase (JAK) inhibitor
- UpadacitinibTyrosine-protein kinase TYK2 inhibitor
- UstekinumabInterleukin-12 inhibitor
Phase 2 4
- InfliximabTNF-alpha inhibitor
- PrednisoneGlucocorticoid receptor agonist
- AbataceptT-lymphocyte activation antigen CD86 inhibitor
- CyclophosphamideDNA inhibitor
How its trials ended
58 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong- Ongoing2136%
- Completed, result not reported2034%
- Status unknown1322%
- Met its primary endpoint35%
- Stopped: enrollment or feasibility12%
| Dec 5, 2025 | TocilizumabTreatment of Takayasu arteritis | Oddifact SAS | Designated |
| Mar 13, 2025 | AdalimumabTreatment of Takayasu arteritis | Oddifact SAS | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA